98 related articles for article (PubMed ID: 19020888)
1. Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: a retrospective study.
Odabasi E; Turan M; Tekbas F; Kutlu M
Arch Gynecol Obstet; 2009 Jun; 279(6):863-7. PubMed ID: 19020888
[TBL] [Abstract][Full Text] [Related]
2. Secondary osteoporosis in women. A retrospective analysis.
Cakir B; Odabasi E; Turan M; Güler S; Kutlu M
Arch Gynecol Obstet; 2002 Aug; 266(4):214-7. PubMed ID: 12192482
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis risk in premenopausal women.
Vondracek SF; Hansen LB; McDermott MT
Pharmacotherapy; 2009 Mar; 29(3):305-17. PubMed ID: 19249949
[TBL] [Abstract][Full Text] [Related]
5. Premenopausal osteoporosis.
Bischoff L; Derk CT
Minerva Med; 2008 Feb; 99(1):55-63. PubMed ID: 18299696
[TBL] [Abstract][Full Text] [Related]
6. [The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis].
Zatońska K; Bolanowski M
Pol Merkur Lekarski; 2000 May; 8(47):356-9. PubMed ID: 10944962
[TBL] [Abstract][Full Text] [Related]
7. [Bone changes in thyrotoxicosis].
Ejima E; Fujiyama K; Kiriyama T; Eguchi K
Nihon Rinsho; 1998 Jun; 56(6):1587-90. PubMed ID: 9648486
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and sex hormone status in intellectually disabled women on progestin-induced amenorrhea.
Arvio M; Kilpinen-Loisa P; Tiitinen A; Huovinen K; Mäkitie O
Acta Obstet Gynecol Scand; 2009; 88(4):428-33. PubMed ID: 19330573
[TBL] [Abstract][Full Text] [Related]
9. Search for secondary osteoporosis: are Z scores useful predictors?
Swaminathan K; Flynn R; Garton M; Paterson C; Leese G
Postgrad Med J; 2009 Jan; 85(999):38-9. PubMed ID: 19240287
[TBL] [Abstract][Full Text] [Related]
10. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of eNOS gene polymorphisms in relation to BMD in postmenopausal women.
Firat SC; Cetin Z; Samanci N; Aydin F; Balci N; Gungor F; Firat MZ; Luleci G; Karauzum SB
Maturitas; 2009 Aug; 63(4):352-6. PubMed ID: 19520527
[TBL] [Abstract][Full Text] [Related]
12. Compliance with osteoporosis treatment guidelines in postmenopausal women.
Mountjoy CR; Shrader SP; Ragucci KR
Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838
[TBL] [Abstract][Full Text] [Related]
13. Low calcaneal bone mineral density and the risk of distal forearm fracture in women and men: a population-based case-control study.
Atroshi I; Ahlander F; Billsten M; Ahlborg HG; Mellström D; Ohlsson C; Ljunggren O; Karlsson MK
Bone; 2009 Oct; 45(4):789-93. PubMed ID: 19539795
[TBL] [Abstract][Full Text] [Related]
14. [Role of cortisol hypersecretion in the pathogenesis of osteoporosis].
Chiodini I; Scillitani A
Recenti Prog Med; 2008 Jun; 99(6):309-13. PubMed ID: 18710063
[TBL] [Abstract][Full Text] [Related]
15. Effect of menopause on gene expression pattern in bone tissue of nonosteoporotic women.
Kósa JP; Balla B; Speer G; Kiss J; Borsy A; Podani J; Takács I; Lazáry A; Nagy Z; Bácsi K; Orosz L; Lakatos P
Menopause; 2009; 16(2):367-77. PubMed ID: 19512969
[TBL] [Abstract][Full Text] [Related]
16. Low bone mass due to sickle cell anemia: is it becoming a real issue?
Sadat-Ali M; Al-Elq AH; Sultan O; Al-Turki H; Bukhari R; Al-Mulhim E
West Afr J Med; 2008 Oct; 27(4):218-23. PubMed ID: 19469399
[TBL] [Abstract][Full Text] [Related]
17. The role of physical activity in the prevention of osteoporosis in postmenopausal women-An update.
Schmitt NM; Schmitt J; Dören M
Maturitas; 2009 May; 63(1):34-8. PubMed ID: 19356867
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study.
Łukaszkiewicz J; Karczmarewicz E; Płudowski P; Jaworski M; Czerwiński E; Lewiński A; Marcinowska-Suchowierska E; Milewicz A; Spaczyński M; Lorenc RS;
Med Sci Monit; 2008 Dec; 14(12):PH65-70. PubMed ID: 19043376
[TBL] [Abstract][Full Text] [Related]
20. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
